A personalized melanoma vaccine, called intismeran, could mark a major advance in cancer treatment. Last week, pharmaceutical companies Merck and Moderna announced clinical trial results showing the vaccine, combined with immunotherapy, reduced the risk of cancer returning or death by 42% compared with immunotherapy alone.
from Medical Xpress - latest medical and health news stories https://ift.tt/JRVyUCK
